(VTRS) Viatris - Ratings and Ratios
Brand, Generic, Biosimilar, Complex, Dose
VTRS EPS (Earnings per Share)
VTRS Revenue
Description: VTRS Viatris October 31, 2025
Viatris Inc. (NASDAQ: VTRS) is a globally diversified healthcare company operating across North America, Europe, Greater China, Japan-Australia-New Zealand (JANZ), and emerging markets. Its business is organized into four geographic segments-Developed Markets, Greater China, JANZ, and Emerging Markets-and it markets a broad portfolio that includes prescription brands, generics, complex generics, and biosimilars covering therapeutic areas such as cardiovascular, CNS, diabetes, oncology, and respiratory diseases. Distribution channels span wholesale, retail, institutional, mail-order, e-commerce, and specialty pharmacies, and the firm also offers ancillary services like diagnostic clinics, educational programs, and digital health tools.
As of FY 2023, Viatris reported revenue of roughly $13.5 billion, with an adjusted EBITDA margin near 12%, reflecting the higher-margin mix from biosimilars and complex generics. The company’s growth is driven by three macro-level factors: (1) an aging global population increasing demand for chronic-disease therapies; (2) accelerating adoption of cost-effective biosimilars as payers tighten reimbursement policies; and (3) a projected 6% CAGR for the worldwide generic drug market through 2029, which benefits Viatris’s scale and diversified geographic footprint. Recent collaborations-such as the long-acting glatiramer acetate depot with Mapi Pharma and a Botox biosimilar with Revance-aim to expand its pipeline and capture additional market share in high-growth therapeutic niches.
If you want a data-rich, model-ready view of Viatris’s valuation dynamics, consider exploring the analytics on ValueRay for a deeper dive.
VTRS Stock Overview
| Market Cap in USD | 11,960m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-11-16 |
VTRS Stock Ratings
| Growth Rating | -24.0% |
| Fundamental | 35.2% |
| Dividend Rating | 61.0% |
| Return 12m vs S&P 500 | -29.4% |
| Analyst Rating | 3.44 of 5 |
VTRS Dividends
| Dividend Yield 12m | 4.74% |
| Yield on Cost 5y | 3.84% |
| Annual Growth 5y | 13.30% |
| Payout Consistency | 57.4% |
| Payout Ratio | 28.9% |
VTRS Growth Ratios
| Growth Correlation 3m | -25.1% |
| Growth Correlation 12m | -36.3% |
| Growth Correlation 5y | -38.5% |
| CAGR 5y | 0.48% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.01 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.03 |
| Sharpe Ratio 12m | 1.21 |
| Alpha | -24.89 |
| Beta | 0.889 |
| Volatility | 34.71% |
| Current Volume | 12204.6k |
| Average Volume 20d | 7561k |
| Stop Loss | 9.8 (-3.2%) |
| Signal | 0.15 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-3.47b TTM) > 0 and > 6% of Revenue (6% = 846.9m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 57.34% (prev 26.79%; Δ 30.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.06b > Net Income -3.47b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.17b) change vs 12m ago -1.52% (target <= -2.0% for YES) |
| Gross Margin 36.61% (prev 40.93%; Δ -4.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.71% (prev 33.62%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.53 (EBITDA TTM -493.3m / Interest Expense TTM 497.9m) >= 6 (WARN >= 3) |
Altman Z'' 0.75
| (A) 0.21 = (Total Current Assets 9.77b - Total Current Liabilities 1.68b) / Total Assets 38.41b |
| (B) 0.00 = Retained Earnings (Balance) 80.0m / Total Assets 38.41b |
| (C) -0.08 = EBIT TTM -3.25b / Avg Total Assets 41.87b |
| (D) -0.11 = Book Value of Equity -2.57b / Total Liabilities 22.84b |
| Total Rating: 0.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.15
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield 6.59% = 3.29 |
| 3. FCF Margin 12.08% = 3.02 |
| 4. Debt/Equity 0.93 = 2.09 |
| 5. Debt/Ebitda -28.19 = -2.50 |
| 6. ROIC - WACC (= -4.43)% = -5.54 |
| 7. RoE -19.92% = -2.50 |
| 8. Rev. Trend -79.06% = -5.93 |
| 9. EPS Trend -65.68% = -3.28 |
What is the price of VTRS shares?
Over the past week, the price has changed by -2.32%, over one month by -0.20%, over three months by +9.00% and over the past year by -19.51%.
Is Viatris a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTRS is around 9.80 USD . This means that VTRS is currently overvalued and has a potential downside of -3.16%.
Is VTRS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the VTRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 12 | 18.6% |
| Analysts Target Price | 12 | 18.6% |
| ValueRay Target Price | 10.5 | 3.9% |
VTRS Fundamental Data Overview November 04, 2025
P/E Forward = 4.1425
P/S = 0.8473
P/B = 0.757
P/EG = 0.0728
Beta = 0.889
Revenue TTM = 14.12b USD
EBIT TTM = -3.25b USD
EBITDA TTM = -493.3m USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 1.79b USD (from shortTermDebt, last quarter)
Debt = 14.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.91b USD (from netDebt column, last quarter)
Enterprise Value = 25.87b USD (11.96b + Debt 14.47b - CCE 566.4m)
Interest Coverage Ratio = -6.53 (Ebit TTM -3.25b / Interest Expense TTM 497.9m)
FCF Yield = 6.59% (FCF TTM 1.70b / Enterprise Value 25.87b)
FCF Margin = 12.08% (FCF TTM 1.70b / Revenue TTM 14.12b)
Net Margin = -24.57% (Net Income TTM -3.47b / Revenue TTM 14.12b)
Gross Margin = 36.61% ((Revenue TTM 14.12b - Cost of Revenue TTM 8.95b) / Revenue TTM)
Gross Margin QoQ = 37.21% (prev 35.68%)
Tobins Q-Ratio = 0.67 (Enterprise Value 25.87b / Total Assets 38.41b)
Interest Expense / Debt = 0.81% (Interest Expense 116.6m / Debt 14.47b)
Taxrate = 97.88% (-212.5m / -217.1m)
NOPAT = -68.9m (EBIT -3.25b * (1 - 97.88%)) [loss with tax shield]
Current Ratio = 5.82 (Total Current Assets 9.77b / Total Current Liabilities 1.68b)
Debt / Equity = 0.93 (Debt 14.47b / totalStockholderEquity, last quarter 15.57b)
Debt / EBITDA = -28.19 (negative EBITDA) (Net Debt 13.91b / EBITDA -493.3m)
Debt / FCF = 8.16 (Net Debt 13.91b / FCF TTM 1.70b)
Total Stockholder Equity = 17.41b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.03% (Net Income -3.47b / Total Assets 38.41b)
RoE = -19.92% (Net Income TTM -3.47b / Total Stockholder Equity 17.41b)
RoCE = -10.77% (EBIT -3.25b / Capital Employed (Equity 17.41b + L.T.Debt 12.79b))
RoIC = -0.22% (negative operating profit) (NOPAT -68.9m / Invested Capital 32.02b)
WACC = 4.21% (E(11.96b)/V(26.43b) * Re(9.29%) + D(14.47b)/V(26.43b) * Rd(0.81%) * (1-Tc(0.98)))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.14%
[DCF Debug] Terminal Value 72.54% ; FCFE base≈1.78b ; Y1≈1.65b ; Y5≈1.51b
Fair Price DCF = 18.92 (DCF Value 21.84b / Shares Outstanding 1.15b; 5y FCF grow -9.15% → 3.0% )
EPS Correlation: -65.68 | EPS CAGR: -58.19% | SUE: -4.0 | # QB: 0
Revenue Correlation: -79.06 | Revenue CAGR: -4.61% | SUE: 2.44 | # QB: 1
Additional Sources for VTRS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle